TABLE 2
FROM:
Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis
Alexander Stojadinovic, Murray F Brennan, Axel Hoos, Atilla Omeroglu, Denis H Y Leung, Maria E Dudas, Aviram Nissan, Carlos Cordon-Cardo and Ronald A Ghossein
BACK TO ARTICLETABLE 2. Adrenal Adenoma versus Carcinoma, Morphologic Features
| Characteristic | Adenoma (n = 37) n (%) | ACC (n = 67) n (%) | P |
|---|---|---|---|
| Median no. slides reviewed | 4 (1–18) | 14 (1–54) | N/A |
| Median tumor weight, gm | 50 (20–60) | 576 (118–2500) | <0.001 |
| Tumor weight category, gm | <0.001 | ||
| 0–100 | 37 (100%) | 4 (9.1%) | |
| 101–250 | 0 (0%) | 6 (13.6%) | |
| 251–1000 | 0 (0%) | 25 (56.8%) | |
| >1000 | 0 (0%) | 9 (20.5%) | |
| Venous invasion | <0.001 | ||
| Yes | 0 (0.0%) | 28 (42.4%) | |
| No | 37 (100%) | 38 (57.6%) | |
| Capsular invasion | <0.001 | ||
| Yes | 0 (0.0%) | 34 (53.1%) | |
| No | 37 (100%) | 30 (46.9%) | |
| Sinus invasion | <0.001 | ||
| Yes | 0 (0.0%) | 63 (94.0%) | |
| No | 37 (100%) | 4 (6.0%) | |
| Adjacent organ invasion | 0.03 | ||
| Yes | 0 (0.0%) | 5 (7.6%) | |
| No | 37 (100%) | 61 (92.4%) | |
| Nuclear grade | <0.001 | ||
| 1 | 2 (5.4%) | 0 (0.0%) | |
| 2 | 30 (81.1%) | 1 (1.5%) | |
| 3 | 5 (13.5%) | 18 (26.9%) | |
| 4 | 0 (0.0%) | 48 (71.6%) | |
| Necrosis | <0.001 | ||
| Yes | 0 (0.0%) | 60 (89.6%) | |
| No | 37 (100%) | 7 (10.4%) | |
| Median mitotic rate/50 hpf | 0 (0–1) | 17 (0–178) | <0.001 |
| Mitotic rate/50 hpf category | <0.001 | ||
| 0–5 | 37 (100%) | 14 (20.9%) | |
| 6–20 | 0 (0.0%) | 22 (32.8%) | |
| 21–50 | 0 (0.0%) | 24 (35.8%) | |
| >50 | 0 (0.0%) | 7 (10.5%) | |
| Atypical mitosis | <0.001 | ||
| Yes | 0 (0.0%) | 46 (68.7%) | |
| No | 37 (100%) | 21 (31.3%) | |
| Architecture | <0.001 | ||
| Diffuse | 0 (0.0%) | 55 (82.1%) | |
| Non-diffuse | 37 (100%) | 12 (17.9%) | |
| Clear cytoplasm | <0.001 | ||
| 0–25% | 5 (13.5%) | 55 (82.1%) | |
| 26–100% | 32 (86.5%) | 12 (17.9%) | |
| Microscopic resection margin | <0.001 | ||
| Negative | 37 (100%) | 21 (33.3%) | |
| Close | 0 (0.0%) | 4 (6.4%) | |
| Positive | 0 (0.0%) | 14 (22.2%) | |
| Unknown | 0 (0.0%) | 24 (38.1%) |
| Number of adverse morphologic features | Metastasizing | ||
|---|---|---|---|
| 0 | 30 (81.1%) | 0 | 0 (0%) |
| 1 | 4 (10.8%) | 0 | 0 (0%) |
| 2 | 3 (8.1%) | 0 | 0 (0%) |
| 3 | 0 | 1 (1.5%) | 0 (0%) |
| 4 | 0 | 2 (3.0%) | 1 (50%) |
| 5 | 0 | 4 (6.0%) | 2 (50%) |
| 6 | 0 | 9 (13.4%) | 7 (77.8%) |
| 7 | 0 | 7 (10.4%) | 7 (100%) |
| 8 | 0 | 7 (10.4%) | 6 (85.7%) |
| 9 | 0 | 18 (26.9%) | 16 (88.9%) |
| 10 | 0 | 13 (19.4%) | 12 (92.3%) |
| 11 | 0 | 5 (7.5%) | 5 (100%) |
| 12 | 0 | 1 (1.5%) | 1 (100%) |
Numbers <67 indicate only those variables that could be determined with certainty after review of the histopathology slides and pathology reports.
